))
Episode 30. Management of High-Risk Myeloma
Manage episode 376847685 series 3369804
Contenido proporcionado por Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
In this episode, we discuss with Dr. Martin Kaiser how to identify and manage newly diagnosed high-risk multiple myeloma in the current era of effective frontline therapies. Here are the key studies that we touched upon:
1. Phase II OPTIMUM (MUKnine) trial in ultra-high-risk myeloma and PCL:
https://pubmed.ncbi.nlm.nih.gov/37315268/
2. Meta-analysis of >2500 patients with chromosome 1q21 abnormalities:
https://pubmed.ncbi.nlm.nih.gov/34092058/
3. Predicting ultra-high risk myeloma by molecular profiling (including SKY92 GEP signature):
https://pubmed.ncbi.nlm.nih.gov/32157174/
4. French data on adverse prognostic impact of del(1p32):
https://pubmed.ncbi.nlm.nih.gov/36375118/
5. S1211 study: The first high-risk enrichment RCT in myeloma (VRD vs Elo-VRD):
https://pubmed.ncbi.nlm.nih.gov/33357482/
6. Outcome of “double-hit” patients in MASTER and Dara-VRD arm of GRIFFIN trial:
https://ashpublications.org/blood/article/140/Supplement%201/10144/488521
7. Impact of Auto-Transplant on decreasing MRD burden in high-risk myeloma (including double-hits):
https://pubmed.ncbi.nlm.nih.gov/35731911/
8. Preliminary results from GMMG-CONCEPT trial in high-risk myeloma:
47 episodios
Compartir
